| 2023-12-31 | Gilead Sciences, Inc. | $95,425 | Grant | Cash or cash equivalent | | | 2023 |
| 2023-12-31 | Medline Industries LP | $4,625 | Debt forgiveness | Cash or cash equivalent | | | 2023 |
| 2023-12-31 | Stryker Corporation | $3,936 | Long term medical supply or device loan | In-kind items and services | PRIME SERIES Device, PATIENT HANDLING - PH | | 2023 |
| 2023-12-31 | Stryker Corporation | $3,230 | Long term medical supply or device loan | In-kind items and services | PRIME SERIES Device, PATIENT HANDLING - PH | | 2023 |
| 2023-12-31 | Stryker Corporation | $2,510 | Debt forgiveness | Cash or cash equivalent | | | 2023 |
| 2023-12-31 | Stryker Corporation | $896 | Debt forgiveness | Cash or cash equivalent | | | 2023 |
| 2023-12-31 | Linvatec Corporation | $804 | Long term medical supply or device loan | In-kind items and services | MENISCAL REPAIR DEVICES Device, ORTHOPEDIC SURGERY | | 2023 |
| 2023-12-31 | Stryker Corporation | $441 | Long term medical supply or device loan | In-kind items and services | ISOFLEX LAL Device, PATIENT HANDLING - PH | | 2023 |
| 2023-12-20 | Gilead Sciences, Inc. | $1,404 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2023 |
| 2023-12-18 | Abbott Laboratories | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | INFINITY Device, Neuromodulation | | 2023 |
| 2023-12-15 | Barco, Inc. | $1,845 | Food and Beverage (15 payments) | In-kind items and services | | | 2023 |
| 2023-12-11 | Boston Scientific Corporation | $1,380 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX TRENDS | 2023 |
| 2023-11-29 | Masimo Corporation | $281 | Long term medical supply or device loan | Cash or cash equivalent | SedLine Device, CARDIOVASCULAR | | 2023 |
| 2023-11-29 | Masimo Corporation | $281 | Long term medical supply or device loan | Cash or cash equivalent | SedLine Device, CARDIOVASCULAR | | 2023 |
| 2023-11-29 | Masimo Corporation | $281 | Long term medical supply or device loan | Cash or cash equivalent | SedLine Device, CARDIOVASCULAR | | 2023 |
| 2023-11-29 | Masimo Corporation | $281 | Long term medical supply or device loan | Cash or cash equivalent | SedLine Device, CARDIOVASCULAR | | 2023 |
| 2023-11-29 | Masimo Corporation | $281 | Long term medical supply or device loan | Cash or cash equivalent | SedLine Device, CARDIOVASCULAR | | 2023 |
| 2023-11-29 | Masimo Corporation | $281 | Long term medical supply or device loan | Cash or cash equivalent | SedLine Device, CARDIOVASCULAR | | 2023 |
| 2023-11-29 | Masimo Corporation | $281 | Long term medical supply or device loan | Cash or cash equivalent | SedLine Device, CARDIOVASCULAR | | 2023 |
| 2023-11-29 | Masimo Corporation | $281 | Long term medical supply or device loan | Cash or cash equivalent | SedLine Device, CARDIOVASCULAR | | 2023 |
| 2023-11-29 | Masimo Corporation | $281 | Long term medical supply or device loan | Cash or cash equivalent | SedLine Device, CARDIOVASCULAR | | 2023 |
| 2023-11-29 | Masimo Corporation | $25 | Long term medical supply or device loan | Cash or cash equivalent | SedLine Device, CARDIOVASCULAR | | 2023 |
| 2023-11-15 | Merit Medical Systems Inc | $279 | Food and Beverage | Cash or cash equivalent | | | 2023 |
| 2023-10-23 | Boston Scientific Corporation | $4,770 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX TRENDS | 2023 |
| 2023-10-19 | ENDOTRONIX, INC. | $43,276 | Research payment | Cash or cash equivalent | CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Device, HEART FAILURE | PROACTIVE-HF | 2023 |
| 2023-10-12 | LANTHEUS MEDICAL IMAGING, INC. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | DEFINITY Drug, CONTRAST AGENT | | 2023 |
| 2023-10-02 | Boston Scientific Corporation | $43,963 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX TRENDS | 2023 |
| 2023-09-29 | Barco, Inc. | $58 | Food and Beverage (2 payments) | In-kind items and services | | | 2023 |
| 2023-09-21 | Volta Medical Inc | $2,126 | Research payment | Cash or cash equivalent | VX1 Device, Cardiovascular | Tailored AF Study (CLIPL-01-002) | 2023 |
| 2023-08-31 | BIOTRONIK INC. | $4,561 | Debt forgiveness | Cash or cash equivalent | | | 2023 |
| 2023-08-31 | BIOTRONIK INC. | $99 | Debt forgiveness | Cash or cash equivalent | | | 2023 |
| 2023-08-27 | Baxter Healthcare | $2,881 | Debt forgiveness | In-kind items and services | Device, Trauma (Emergency, Injury, Surgery) | | 2023 |
| 2023-08-25 | Gilead Sciences, Inc. | $34,000 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Incidence of Acute Kidney Disease in COVID-19 Patients Receiving Remdesivir | 2023 |
| 2023-08-25 | Gilead Sciences, Inc. | $1,202 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2023 |
| 2023-08-24 | Chiesi USA, Inc. | $11,750 | Research payment | Cash or cash equivalent | | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2023 |
| 2023-08-24 | Novocure Inc. | $6,750 | Research payment | Cash or cash equivalent | | EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi | 2023 |
| 2023-08-11 | Boston Scientific Corporation | $1,364 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX TRENDS | 2023 |
| 2023-08-08 | Boston Scientific Corporation | $272 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX TRENDS | 2023 |
| 2023-07-31 | AstraZeneca Pharmaceuticals LP | $85 | Education | In-kind items and services | IRESSA Drug, Oncology | | 2023 |
| 2023-07-17 | Gilead Sciences, Inc. | $12,000 | Research payment | Cash or cash equivalent | | Acceptability of Long-Acting Injectable Lenacapavir Among Heavily Treatment Experienced Individuals with HIV within the | 2023 |
| 2023-06-21 | Gilead Sciences, Inc. | $1,404 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2023 |
| 2023-06-16 | Boston Scientific Corporation | $818 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX TRENDS | 2023 |
| 2023-06-12 | Boston Scientific Corporation | $3,812 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX TRENDS | 2023 |
| 2023-06-02 | Boston Scientific Corporation | $272 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX TRENDS | 2023 |
| 2023-05-15 | Boston Scientific Corporation | $371 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX TRENDS | 2023 |
| 2023-05-08 | Boston Scientific Corporation | $272 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX TRENDS | 2023 |
| 2023-05-05 | Siemens Medical Solutions USA, Inc. | $2,310 | Research payment | Cash or cash equivalent | | PE OUS Study | 2023 |
| 2023-03-30 | Novocure Inc. | $2,700 | Research payment | Cash or cash equivalent | | EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi | 2023 |
| 2023-03-24 | Volta Medical Inc | $3,847 | Research payment | Cash or cash equivalent | VX1 Device, Cardiovascular | Tailored AF Study (CLIPL-01-002) | 2023 |
| 2023-03-15 | Merck Sharp & Dohme LLC | $60,114 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | STUDY NAME#Impact of an Acute-Care Antimicrobial Stewardship Program's Interventional Collaboration on Antimicrobial Use | 2023 |
| 2023-03-02 | Stryker Corporation | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SURPASS EVOLVE Device, FLOW DIVERTER | | 2023 |
| 2023-03-02 | Masimo Corporation | $360 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-03-02 | Masimo Corporation | $360 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-03-02 | Masimo Corporation | $360 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-03-02 | Masimo Corporation | $360 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-02-22 | Gilead Sciences, Inc. | $1,202 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2023 |
| 2023-02-21 | Boston Scientific Corporation | $16,131 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX TRENDS | 2023 |
| 2023-02-21 | Boston Scientific Corporation | $4,500 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX TRENDS | 2023 |
| 2023-02-16 | KCI USA, Inc. | $1,950 | Debt forgiveness | Cash or cash equivalent | Bair Hugger Device, Thermal Regulation Systems & Temp Mgmt Systems | | 2023 |
| 2023-02-10 | Olympus America Inc. | $500 | Debt forgiveness | In-kind items and services | EVIS EXERA lll COLONOVIDEOSCOPE Device, Gastroenterology | | 2023 |
| 2023-02-08 | Gilead Sciences, Inc. | $6,375 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2023 |
| 2023-02-01 | Novartis Pharmaceuticals Corporation | $18,650 | Research payment | Cash or cash equivalent | ENTRESTO Drug, Cardiology/Vascular Diseases | Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE-HFpEF) | 2023 |
| 2023-01-31 | BIOTRONIK INC. | $1,586 | Debt forgiveness | Cash or cash equivalent | | | 2023 |
| 2023-01-27 | Volta Medical Inc | $1,012 | Research payment | Cash or cash equivalent | VX1 Device, Cardiovascular | Tailored AF Study (CLIPL-01-002) | 2023 |
| 2023-01-26 | Volta Medical Inc | $3,000 | Research payment | Cash or cash equivalent | VX1 Device, Cardiovascular | Tailored AF Study (CLIPL-01-002) | 2023 |
| 2023-01-26 | Boston Scientific Corporation | $272 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX TRENDS | 2023 |
| 2023-01-25 | Novartis Pharmaceuticals Corporation | $36,110 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy | 2023 |
| 2023-01-17 | Boston Scientific Corporation | $15,774 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX TRENDS | 2023 |
| 2023-01-11 | Boston Scientific Corporation | $272 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product CRM | LUX DX TRENDS | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $432 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $200 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $200 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
| 2023-01-01 | Masimo Corporation | $200 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, CARDIOVASCULAR | | 2023 |
Comments